Obstetrics & gynaecology

Higher-dose DHA in pregnancy tied to fewer early preterm births

(HealthDay)—Supplementation with a higher dose of docosahexaenoic acid (DHA) versus the standard prenatal dose during the second half of pregnancy is associated with a lower rate of early preterm births, according to a study published online May 17 in EClinicalMedicine.

Susan E. Carlson, Ph.D., from University of Kansas in Kansas City, and colleagues randomly assigned women with singleton pregnancies and 12 to 20 weeks of gestation to DHA supplementation (1,000 mg: 576 women; 200 mg: 524 women).

The researchers found that the higher DHA dose was associated with a lower early preterm birth rate (1.7 versus 2.4 percent; posterior probability [pp] = 0.81). Findings were even stronger among participants with low DHA status at enrollment (2.0 versus 4.1 percent; pp = 0.93). A dose effect was not seen among participants with high DHA status at enrollment (1,000 mg: 1.4 percent; 200 mg: 1.1 percent; pp = 0.57). There were fewer serious adverse events (maternal: chorioamnionitis, premature rupture of membranes, pyelonephritis; neonatal: feeding, genitourinary and neurologic problems; all pp > 0.90) associated with the higher dose.

“Clinicians could consider prescribing 1,000 mg DHA daily during pregnancy to reduce early preterm birth in women with low DHA status if they are able to screen for DHA,” the authors write.


Study shows early preterm births can be decreased with DHA supplementation


More information:
Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.

Citation:
Higher-dose DHA in pregnancy tied to fewer early preterm births (2021, June 21)
retrieved 21 June 2021
from https://medicalxpress.com/news/2021-06-higher-dose-dha-pregnancy-tied-early.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.